Pure Global

A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. - Trial NCT06339216

Access comprehensive clinical trial information for NCT06339216 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chinese PLA General Hospital and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06339216
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06339216
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
A Phase II Clinical Study of Adebrelimab Injection in Combination With Apatinib and Paclitaxel for Injection (Albumin-bound) as Second-line Therapy in Patients With Advanced Gastric Cancer Who Had Previously Received Immunotherapy.

Study Focus

Gastric Cancer

Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)

Interventional

drug

Sponsor & Location

Chinese PLA General Hospital

Timeline & Enrollment

Phase 2

Mar 20, 2024

Nov 30, 2026

30 participants

Primary Outcome

ORR

Summary

Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for
 Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer
 Previously Treated with Immunotherapy

ICD-10 Classifications

Gastric ulcer
Malignant neoplasm of stomach
Malignant neoplasm: Body of stomach
Carcinoma in situ: Stomach
Malignant neoplasm: Stomach, unspecified

Data Source

ClinicalTrials.gov

NCT06339216

Non-Device Trial